Qingdao Dingxing Qiguang Medical Industry Investment Fund Partnership (Limited Partnership), managed by Guojin Dingxing Investment Co., Ltd. completed the acquisition of 5.0025% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE : 688278) from Tonghua Dongbao Pharmaceutical Co., Ltd..
January 26, 2022
Share
Qingdao Dingxing Qiguang Medical Industry Investment Fund Partnership (Limited Partnership), managed by Guojin Dingxing Investment Co., Ltd. entered into a share transfer agreement to acquire a 5.0025% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE : 688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for approximately CNY 460 million on January 5, 2022. The consideration comprises of 20% 0f total consideration CNY 92 million to be paid within three working days from the effective date of the share transfer agreement and remaining transfer price CNY 368 million to be paid at closing. The CNY 22.608 is the per share price. Prior to transaction, Qingdao Dingxing held no stake in Xiamen Amoytop and Tonghua holds 27.40% stake in it. The transaction was approved at the 23rd meeting of the tenth board of directors of the Tonghua.
Qingdao Dingxing Qiguang Medical Industry Investment Fund Partnership (Limited Partnership), managed by Guojin Dingxing Investment Co., Ltd. completed the acquisition of 5.0025% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE : 688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) on January 27, 2022.
XIAMEN AMOYTOP BIOTECH CO., LTD is a China-based company mainly engaged in the biopharmaceutical business, including the research, development, manufacture and sales of recombinant proteins and their long-acting modified drugs. The Company's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The Company distributes its products within domestic market and to overseas markets.
Qingdao Dingxing Qiguang Medical Industry Investment Fund Partnership (Limited Partnership), managed by Guojin Dingxing Investment Co., Ltd. completed the acquisition of 5.0025% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE : 688278) from Tonghua Dongbao Pharmaceutical Co., Ltd..